Skip to Main Content

Why is everyone so down on biotech’s household names? How do you become a day trader? And if a stock gets downgraded in an analyst note, should anyone care?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with biotech investor and philanthropist Sheff Station about how he got into biotech investing. Then we’ll take a look back at the biggest stories and surprises from the first half of 2018, followed by a look ahead to the events that will shape the rest of the year for the drug industry. And then we’ll talk about some soul-searching analyst research that questions the very utility of analyst research.


For more on what we cover, here’s a look at how investors are bored with Big Biotech; here’s a rundown of recent IPOs; here’s what we’re looking out for in the coming months; and here’s more on that analyst research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!